Chinese biopharma Innovent Biologics (HKEX: 01801) and US pharma major Eli Lilly (NYSE: LLY) have presented results of the Phase III ORIENT-3 study at the American Association for Cancer Research (AACR) Annual Meeting 2021.
ORIENT-3 is evaluating Tyvyt (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).
"The anti-PD-1 monoclonal antibody sintilimab significantly improved OS"A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze